Enhanced Immunogenicity of Engineered HER2 Antigens Potentiates Antitumor Immune Responses

Jeon, Insu; Lee, Jeong-Mi; Shin, Kwang‐Soo; Kang, Taewook; Park, Myung Hwan; Seo, Hyungseok; Song, Boyeong; Koh, Choong-Hyun; Choi, Jong-Woo; Shin, Young Kee; Kim, Il‐Kyu; Kang, Chang–Yuil

doi:10.3390/vaccines8030403

Cited by 3 publications

(1 citation statement)

References 56 publications

(69 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For instance, adenoviral vectors were used to introduce sequence coding of the epitopes of the Human Epidermal Growth Factor 2 (HER-2) into B cells, which led to the generation of antibodies against HER-2 and of a cytotoxic T lymphocyte (CTL) immune response. Following infusion of these cells in vivo, both reduction in tumor growth and improved survival were observed [ 25 ]. Further enhancing adenovirus efficacy, modification of the structure of fiber virion surface protein was performed to promote B cell transduction.…”

Section: Adoptive Cell Therapies With B Cells Loaded With Tumor Antigensmentioning

confidence: 99%

Exploiting B Cell Transfer for Cancer Therapy: Engineered B Cells to Eradicate Tumors

Page

Hubert

Fusil

et al. 2021

IJMS

View full text Add to dashboard Cite

Nowadays, cancers still represent a significant health burden, accounting for around 10 million deaths per year, due to ageing populations and inefficient treatments for some refractory cancers. Immunotherapy strategies that modulate the patient’s immune system have emerged as good treatment options. Among them, the adoptive transfer of B cells selected ex vivo showed promising results, with a reduction in tumor growth in several cancer mouse models, often associated with antitumoral immune responses. Aside from the benefits of their intrinsic properties, including antigen presentation, antibody secretion, homing and long-term persistence, B cells can be modified prior to reinfusion to increase their therapeutic role. For instance, B cells have been modified mainly to boost their immuno-stimulatory activation potential by forcing the expression of costimulatory ligands using defined culture conditions or gene insertion. Moreover, tumor-specific antigen presentation by infused B cells has been increased by ex vivo antigen loading (peptides, RNA, DNA, virus) or by the sorting/ engineering of B cells with a B cell receptor specific to tumor antigens. Editing of the BCR also rewires B cell specificity toward tumor antigens, and may trigger, upon antigen recognition, the secretion of antitumor antibodies by differentiated plasma cells that can then be recognized by other immune components or cells involved in tumor clearance by antibody-dependent cell cytotoxicity or complement-dependent cytotoxicity for example. With the expansion of gene editing methodologies, new strategies to reprogram immune cells with whole synthetic circuits are being explored: modified B cells can sense disease-specific biomarkers and, in response, trigger the expression of therapeutic molecules, such as molecules that counteract the tumoral immunosuppressive microenvironment. Such strategies remain in their infancy for implementation in B cells, but are likely to expand in the coming years.

show abstract

Section: Adoptive Cell Therapies With B Cells Loaded With Tumor Antigensmentioning

confidence: 99%

Exploiting B Cell Transfer for Cancer Therapy: Engineered B Cells to Eradicate Tumors

Page

Hubert

Fusil

et al. 2021

IJMS

View full text Add to dashboard Cite

show abstract

Hypofunction of macrophage chemotaxis contributes to defective efficacy of herceptin in HER2-positive breast cancer patients

Song,

Geng,

et al. 2024

Molecular & Cellular Oncology

View full text Add to dashboard Cite

Targeting Cancer: Microenvironment and Immunotherapy Innovations

Padzińska-Pruszyńska,

Taciak,

Kiraga

et al. 2024

IJMS

View full text Add to dashboard Cite

In 2024, the United States was projected to experience 2 million new cancer diagnoses and approximately 611,720 cancer-related deaths, reflecting a broader global trend in which cancer cases are anticipated to exceed 35 million by 2050. This increasing burden highlights ongoing challenges in cancer treatment despite significant advances that have reduced cancer mortality by 31% since 1991. Key obstacles include the disease’s inherent heterogeneity and complexity, such as treatment resistance, cancer stem cells, and the multifaceted tumor microenvironment (TME). The TME—comprising various tumor and immune cells, blood vessels, and biochemical factors—plays a crucial role in tumor growth and resistance to therapies. Recent innovations in cancer treatment, particularly in the field of immuno-oncology, have leveraged insights into TME interactions. An emerging example is the FDA-approved therapy using tumor-infiltrating lymphocytes (TILs), demonstrating the potential of cell-based approaches in solid tumors. However, TIL therapy is just one of many strategies being explored. This review provides a comprehensive overview of the emerging field of immuno-oncology, focusing on how novel therapies targeting or harnessing components of the TME could enhance treatment efficacy and address persistent challenges in cancer care.

show abstract

Enhanced Immunogenicity of Engineered HER2 Antigens Potentiates Antitumor Immune Responses

Cited by 3 publications

References 56 publications

Exploiting B Cell Transfer for Cancer Therapy: Engineered B Cells to Eradicate Tumors

Exploiting B Cell Transfer for Cancer Therapy: Engineered B Cells to Eradicate Tumors

Hypofunction of macrophage chemotaxis contributes to defective efficacy of herceptin in HER2-positive breast cancer patients

Targeting Cancer: Microenvironment and Immunotherapy Innovations

Contact Info

Product

Resources

About